Effect of early application of liraglutide on visceral obesity

VernacularTitle:利拉鲁肽早期应用对内脏型肥胖的影响
Author: Weigang ZHAO
Publication Type:Journal Article
Keywords: Diabetes mellitus,type2; Obesity,abdominal; Insulin resistance; Liraglutide; Body weight; Intra-abdominal fat
From: Chinese Journal of Endocrinology and Metabolism 2014;30(10):872-875
CountryChina
Language:Chinese
Abstract: Visceral obesity is closely related to development of insulin resistance,metabolic syndrome,type 2 diabetes mellitus,and cardiovascular disease.Visceral obesity leads to increased insulin resistance,which is an important risk factor for the development of type 2 diabetes mellitus.Weight loss,especially reduction of visceral adipose,can improve insulin sensitivity effectively,and thereby reduce the risk of obesity-related type 2 diabetes mellitus and cardiovascular disease.Studies have confirmed that liraglutide,as an analogue of human glucagon like peptide-1 (GLP-1),when used early in type 2 diabetes patients with obesity,can not only control glycemia and protect β-cells,but also significantly lose weight,and its benefit on weight is mainly based on the reduction of visceral adipose.Therefore,early application of liragtutide in type 2 diabetes with obesity will provide a new choice for the treatment of type 2 diabetes mellitus.